bluebird bio (NASDAQ:BLUE) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of bluebird bio (NASDAQ:BLUE) in a research report report published on Tuesday. The firm issued a sell rating on the biotechnology company’s stock.

Other equities research analysts have also recently issued reports about the company. Baird R W cut bluebird bio from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 21st. Wells Fargo & Company lowered their price target on bluebird bio from $40.00 to $5.00 and set an “equal weight” rating on the stock in a research report on Monday, February 24th. Barclays lowered their price target on bluebird bio from $40.00 to $8.00 and set an “overweight” rating on the stock in a research report on Monday, March 31st. Finally, JPMorgan Chase & Co. upgraded bluebird bio from an “underweight” rating to a “neutral” rating in a research report on Monday, February 24th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $44.60.

bluebird bio Trading Down 0.7 %

NASDAQ BLUE opened at $4.05 on Tuesday. The company has a market capitalization of $39.65 million, a PE ratio of -0.11 and a beta of 0.41. The company has a fifty day moving average of $4.23 and a 200 day moving average of $6.76. bluebird bio has a 1 year low of $3.56 and a 1 year high of $28.60. The company has a debt-to-equity ratio of 0.37, a current ratio of 0.51 and a quick ratio of 0.33.

Hedge Funds Weigh In On bluebird bio

Several hedge funds and other institutional investors have recently made changes to their positions in BLUE. Barclays PLC lifted its position in shares of bluebird bio by 273.7% in the third quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock valued at $130,000 after acquiring an additional 184,605 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of bluebird bio by 3.7% in the third quarter. Geode Capital Management LLC now owns 4,683,042 shares of the biotechnology company’s stock valued at $2,433,000 after acquiring an additional 166,771 shares in the last quarter. State Street Corp lifted its position in shares of bluebird bio by 1.1% in the third quarter. State Street Corp now owns 3,841,923 shares of the biotechnology company’s stock valued at $1,996,000 after acquiring an additional 43,382 shares in the last quarter. Regeneron Pharmaceuticals Inc. purchased a new position in shares of bluebird bio in the fourth quarter valued at approximately $175,000. Finally, Bank of New York Mellon Corp lifted its position in bluebird bio by 12.7% during the first quarter. Bank of New York Mellon Corp now owns 32,759 shares of the biotechnology company’s stock worth $160,000 after buying an additional 3,686 shares in the last quarter. Hedge funds and other institutional investors own 87.43% of the company’s stock.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.